PINE BROOK, N.J., Sept. 18 /PRNewswire/ -- Elusys Therapeutics, Inc.
(Elusys), a privately held biopharmaceutical company developing
antibody-based therapies for the treatment of life-threatening infectious
diseases, today announced the appointment of Robert D. Love as Chief
Financial Officer.
Elizabeth G. Posillico, Ph.D., President and Chief Executive Officer,
commented on the appointment, "Bob brings a wealth of expertise in
corporate finance, operations and investor relations to Elusys. We are
extremely pleased that he has joined the company as part of the senior
management team."
Mr. Love has more than 30 years of financial management experience at
both privately held and publicly traded biopharmaceutical corporations.
Most recently, he served as Executive Vice President and Chief Financial
Officer of Alfacell Corporation, a biopharmaceutical company developing
novel therapeutics for cancer and other life-threatening diseases.
Previously, Mr. Love served as Senior Vice President, Chief Financial
Officer and Chief Operating Officer of Trigenesis Therapeutics, a privately
held dermatology company.
Prior to his work at Trigenesis, Mr. Love served as Senior Vice
President, Business Partnering and Senior Vice President, Finance and
Acquisitions at Quintiles Transnational Corporation/Innovex. Mr. Love also
held several senior management positions at SmithKline Beecham, including
Vice President and Director, Strategic Product Development and Vice
President, and Chief Financial Officer in the United Kingdom. Mr. Love
began his career in 1972 as an accountant at Coopers and Lybrand. He earned
a B.A. in Accounting from Rutgers University and an M.B.A. in Finance and
Marketing from Villanova University.
About Elusys
Elusys is a privately held biopharmaceutical company focused on the
development of antibody-based therapeutics for the treatment of life-
threatening infectious disease. In March of 2007, the company's anthrax
antibody therapeutic, Anthim(TM), was selected to R&D Directions' list of
"100 Great Investigational Drugs."
Current venture investors include Essex Woodlands Health Ventures LLC,
Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer.
For more information please visit http://www.elusys.com.
SOURCE Elusys Therapeutics, Inc.
 back to top
Related links:
http://www.elusys.com
CONTACT:
Tim Allison of LaVoie Group, +1-978-745-4200,
ext. 102, Tallison@lavoiegroup.com, for Elusys Therapeutics, Inc.
|
